[1] Arps DP,Jorns JM,Zhao L,et al.Re-excision rates of invasiveductal carcinoma with lobular features compared with invasiveductal carcinomas and invasive lobular carcinomas of thebreast[J].Ann Surg Oncol,2014(21):4152-4158.
[2] Zhao Y,Li RG,Song J.The present situation and prospect for gene therapy of breast cancer[J].Cancer Genetics and Epigenetics,2014,2(2):1-8.
[3] LIU W,WANG YR,WANG YX.Predictive values after neoadjuvant chemotherapy pathologic complete response for patient outcome in different molecular subtypes of breast cancer[J].Modern Oncology,2018,26(13):2118-2122.[刘伟,王燕荣,王永兴.新辅助化疗后的病理完全缓解及其对不同分子亚型乳腺癌的预后价值[J].现代肿瘤医学,2018,26(13):2118-2122.]
[4]Guiu S,Wolfer A,Jacot W,et al.Invasive lobular breast cancer and its variants:How special are they for systemic therapy decisions[J]?Crit Rev Oncol Hematol,2014,92(3):235-257.
[5] Wasif N,Maggard MA,Ko CY,et al.Invasive lobular vs ductal breast cancer:A stage-matched comparison of outcomes[J].Ann Surg Oncol,2010(17):1862-1869.
[6] Cho N,Im SA,Cheon GJ,et al.Integrated 18F-FDG PET/MRI in breast cancer:Early predictionof response to neoadjuvant chemotherapy[J].Eur J Nucl Med MolImaging,2018,45(3):328-339.
[7] Mottaghy FM.Is the whole larger than the sum of the parts?Integrated PET/MRI as a tool for response prediction[J].Eur J Nucl Med Mol Imaging,2018,45(1):325-327.
[8] Vachon CM,Scott CG,Fasching PA,et al.Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk[J].Cancer Epidemiol Biomarkers Prev,2012,21(2):1156-1166.
[9] Zhao Y,Zhang DW.Biomarker alteration to neoadjuvant chemotherapy predict pathological response and prognosis in breast cancer patients[J].Cancer Genetics and Epigenetics,2018,6(1):1-12.
[10] Sohn G,Lee JW,Park SW,et al.Reliability of the percent density in digital mammography with a semi-automated thresholding method[J].J Breast Cancer,2014,17(2):174-179.
[11] Destounis S,Arieno A,Morgan R.Initial experience with the New York State breast density informlaw at a community-based breast center[J].J Ultrasound Med,2015(34):993-1000.
[12] Chinese Anti-Cancer Association.Guidelines and guidelines for the diagnosis and treatment of breast cancer in Chinese cancer society[J].China Oncology,2015,25(9):696.[中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):696.]
[13] Arpino G,Bardou VJ,Clark GM,et al.Infiltrating lobular carcinoma of thebreast:Tumor characteristics and clinical outcome[J].Breast Cancer Res,2004(6):R149-R156.
[14] Anastasiadi Z,Lianos GD,Ignatiadou E,et al.Breast cancer in young women:An overview[J].Updates Surg,2017,69(3):313-317.
[15] Price ER,Hargreaves J,Lipson JA,et al.The California breast density information group:A collaborative response to the issues of breast density,breast cancer risk,and breast density notification legislation[J].Radiology,2013(269):887-892.
[16] Antropova N,Huynh BQ,Giger ML.A deep feature fusion methodology for breastcancer diagnosis demonstrated on three imagingmodality datasets[J].Med Phys,2017(44):5162-5171.
[17] Drukker K,Li H,Antropova N,et al.Most-enhancing tumor volume by MRIradiomics predicts recurrence-free survival "early on" in neoadjuvant treatmentof breast cancer[J].Cancer Imaging,2018(18):12-18.
[18] Sprague BL,Gangnon RE,Burt V,et al.Prevalence of mammographically dense breasts in theUnited States[J].J Natl Cancer Inst,2014(106):1-6.
[19] Mann RM,Hoogeveen YL,Blickman JG,et al.MRI comparedto conventional diagnostic work-up in the detection and evaluationof invasive lobular carcinoma of the breast:A review ofexisting literature[J].Breast Cancer Res Treat,2008(107):1-14.
[20] Heil J,Buehler A,Golatta M,et al.Do patients with invasivelobular breast cancer benefit in terms of adequate change insurgical therapy from a supplementary preoperative breast MRI[J]?Ann Oncol,2012(23):98-104.
[21] ZHANG Q,YAO DW.The value of color doppler ultrasound in the diagnosis of contralateral breast cancer in patients with dense breast and history of breast cancer[J].Modern Oncology,2019,27(6):1043-1047.[张茜,么大伟.彩色多普勒超声在诊断致密型乳腺癌患者术后对侧乳腺癌中的价值[J].现代肿瘤医学,2019,27(6):1043-1047.]
[22] Williams LA,Hoadley KA,Nichols HB,et al.Differences in race,molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas[J].Cancer Causes Control,2019,30(1):31-39.
[23] Chen XH,Zhang WW,Wang J.21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer[J].Biomark Med,2019,13(2):83-93.
[24] Christgen M,Bartels S,Radner M,et al.ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling[J].Genes Chromosomes Cancer,2019,58(3):175-185.
[25] Kumar A,Rao A,Bhavani S,et al.Automated analysis of immunohistochemistry images identifies candidate location biomarkers for cancers[J].Proc Natl Acad Sci USA,2014,111(51):18249-18254.
[26] Grimm LJ,Saha A,Ghate SV,et al.Relationship between background parenchymal enhancement on high-risk screening MRI and future breast cancer risk[J].Acad Radiol,2019,26(1):69-75.
[27] Ko ES,Morris EA.Abbreviated magnetic resonance imaging for breast cancer screening:Concept,early results,and considerations[J].Korean J Radiol,2019,20(4):533-541.
[28] Houssami N,Turner RM,Morrow M.Meta-analysis of preoperativemagnetic resonance imaging(MRI) and surgicaltreatment for breast cancer[J].Breast Cancer Res Treat,2017(165):273-283.
[29]Bansal GJ,Santosh D,Davies EL.Selective magneticresonance imaging(MRI) in invasive lobular breast cancerbased on mammographic density:Does it lead to an appropriatechange in surgical treatment[J]?Br J Radiol,2016(89):1-7.
[30]Mann RM,Loo CE,Wobbes T,et al.The impact of preoperativebreast MRI on the re-excision rate in invasive lobular carcinoma of the breast[J].Breast Cancer Res Treat,2010(119):415-422.